Enteroccoccus faecalis is a commensal that is responsible for numerous infections in surgical sites, urinary tract and bloodstream. It is of growing concern given its propensity to affect the elderly population where there is a high prevalence of undiagnosed degenerative valvular disease and the with more invasive procedures and implanted medical devices. Its actions are mediated by specific characteristics of the bacterium such as pili activity and biofilm formation. This confers significant resistance toward a multitude of antibiotic therapy, especially in endocarditis. The current guidelines advocate antimicrobial therapy but the emergence of resistant strains has added a degree of complexity to the management of these patients, especially with the advent of transcatheter therapies which are often used in patients who are poor surgical candidates. Their presentations are often variable with generalized symptoms and can be diagnostically challenging. We present our experience of a case study involving an octogenarian with a TAVI valve who developed endocarditis and performed a literature review to highlight treatment algorithms for these cases.

The discovery of microRNAs and their role in disease today represents a substantial breakthrough that has inspired and propagating research on microRNAs as targets for diagnosis and therapy. Cardiovascular disease is an area where the limitations of early diagnosis and conventional pharmacotherapy are evident and deserve attention. Thus microRNA-based drugs have substantial potential for development. Research and its application can progress considerably as witnessed in preclinical and clinical trials. The use of miRNAs remains experimental at the time of writing but has a promising role in the diagnosis and prognosis of a variety of acute coronary syndrome presentations. Its use, alone or in combination with currently available biomarkers, could be adopted soon, especially if diagnostic ambiguity exists. In this review, we explore the current state of knowledge about microRNAs as potential targets for diagnosis and therapy in the cardiovascular system. We report recent improvements in the acknowledgment and characterization of microRNAs focusing on clinical translation. The new dares and outlooks toward clinical application are discussed.